AIMS: Current guidelines prefer primary percutaneous coronary intervention (pPCI) over fibrinolysis in the treatment of acute ST-elevation myocardial infarction (STEMI). Pre-hospital fibrinolysis followed by early invasive evaluation is an alternative that we have used in patients presenting within three hours of symptom onset. We made a survey of patients suffering an acute STEMI over one year to assess mortality and adverse events following either pPCI or fibrinolysis. METHODS AND RESULTS: Of the 448 consecutive STEMI patients, 194 were treated with pPCI and 176 underwent fibrinolysis; 78 patients received no reperfusion treatment within 12 hours (NRT group). The median TIMI risk scores were 4.0, 3.0 and 4.0 in the pPCI, fibrinolysis and NRT groups, respectively (p<0.001). Mortality at one year was 14.4% following pPCI, 5.1% following fibrinolysis and 12.8% in the NRT group (p=0.011 across all groups and p=0.003 between pPCI and fibrinolysis, adjusted for differences in risk factors). The one-year composite of cardiovascular death, stroke, reinfarction and new revascularization was 20.1%, 18.2% and 26.9% for the pPCI, fibrinolysis and NRT groups, respectively (p=NS). In patients presenting within three hours of symptom onset, one-year mortality was 3.7% in the fibrinolysis group (n=163) and 15.3% in the pPCI group (n=118) (adjusted p =0.001), while the composite of adverse events was 16.6% in the former group and 19.5% in the latter (p=NS). CONCLUSION: Pre-hospital fibrinolysis followed by routine early invasive evaluation provides an excellent reperfusion strategy for low-risk STEMI patients presenting early after symptom onset.
AIMS: Current guidelines prefer primary percutaneous coronary intervention (pPCI) over fibrinolysis in the treatment of acute ST-elevation myocardial infarction (STEMI). Pre-hospital fibrinolysis followed by early invasive evaluation is an alternative that we have used in patients presenting within three hours of symptom onset. We made a survey of patients suffering an acute STEMI over one year to assess mortality and adverse events following either pPCI or fibrinolysis. METHODS AND RESULTS: Of the 448 consecutive STEMI patients, 194 were treated with pPCI and 176 underwent fibrinolysis; 78 patients received no reperfusion treatment within 12 hours (NRT group). The median TIMI risk scores were 4.0, 3.0 and 4.0 in the pPCI, fibrinolysis and NRT groups, respectively (p<0.001). Mortality at one year was 14.4% following pPCI, 5.1% following fibrinolysis and 12.8% in the NRT group (p=0.011 across all groups and p=0.003 between pPCI and fibrinolysis, adjusted for differences in risk factors). The one-year composite of cardiovascular death, stroke, reinfarction and new revascularization was 20.1%, 18.2% and 26.9% for the pPCI, fibrinolysis and NRT groups, respectively (p=NS). In patients presenting within three hours of symptom onset, one-year mortality was 3.7% in the fibrinolysis group (n=163) and 15.3% in the pPCI group (n=118) (adjusted p =0.001), while the composite of adverse events was 16.6% in the former group and 19.5% in the latter (p=NS). CONCLUSION: Pre-hospital fibrinolysis followed by routine early invasive evaluation provides an excellent reperfusion strategy for low-risk STEMI patients presenting early after symptom onset.
Authors: Anthony H Gershlick; Amanda Stephens-Lloyd; Sarah Hughes; Keith R Abrams; Suzanne E Stevens; Neal G Uren; Adam de Belder; John Davis; Michael Pitt; Adrian Banning; Andreas Baumbach; Man Fai Shiu; Peter Schofield; Keith D Dawkins; Robert A Henderson; Keith G Oldroyd; Robert Wilcox Journal: N Engl J Med Date: 2005-12-29 Impact factor: 91.245
Authors: Marc J Claeys; Antoine de Meester; Carl Convens; Philippe Dubois; Jean Boland; Herbert De Raedt; Pascal Vranckx; Patrick Coussement; Sofie Gevaert; Peter Sinnaeve; Patrick Evrard; Christophe Beauloye; Marc Renard; Christiaan Vrints Journal: Arch Intern Med Date: 2011-03-28
Authors: Cynthia M Westerhout; Eric Bonnefoy; Robert C Welsh; Philippe Gabriel Steg; Florent Boutitie; Paul W Armstrong Journal: Am Heart J Date: 2011-02 Impact factor: 4.749
Authors: Etienne Puymirat; Tabassome Simon; Philippe Gabriel Steg; François Schiele; Pascal Guéret; Didier Blanchard; Khalife Khalife; Patrick Goldstein; Simon Cattan; Laurent Vaur; Jean-Pierre Cambou; Jean Ferrières; Nicolas Danchin Journal: JAMA Date: 2012-09-12 Impact factor: 56.272
Authors: Petr Widimsky; William Wijns; Jean Fajadet; Mark de Belder; Jiri Knot; Lars Aaberge; George Andrikopoulos; Jose Antonio Baz; Amadeo Betriu; Marc Claeys; Nicholas Danchin; Slaveyko Djambazov; Paul Erne; Juha Hartikainen; Kurt Huber; Petr Kala; Milka Klinceva; Steen Dalby Kristensen; Peter Ludman; Josephina Mauri Ferre; Bela Merkely; Davor Milicic; Joao Morais; Marko Noc; Grzegorz Opolski; Miodrag Ostojic; Dragana Radovanovic; Stefano De Servi; Ulf Stenestrand; Martin Studencan; Marco Tubaro; Zorana Vasiljevic; Franz Weidinger; Adam Witkowski; Uwe Zeymer Journal: Eur Heart J Date: 2009-11-19 Impact factor: 29.983
Authors: Kimmo Koivula; Kjell Nikus; Juho Viikilä; Jyrki Lilleberg; Heini Huhtala; Yochai Birnbaum; Markku Eskola Journal: Ann Noninvasive Electrocardiol Date: 2018-09-06 Impact factor: 1.468